Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo

T E Bapiro1, K K Frese1,3, A Courtin1,4, J L Bramhall1, B Madhu1, N Cook1,3, A Neesse1,5, J R Griffiths1, D A Tuveson2, D I Jodrell*,1 and F M Richards*,1

1Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Box 278, Robinson Way, Cambridge CB2 0RE, UK and 2Cold Spring Harbor Laboratory, 1 Bungtown Road, Cold Spring Harbor, NY 11724, USA

Background: The modest benefits of gemcitabine (dFdC) therapy in patients with pancreatic ductal adenocarcinoma (PDAC) are well documented, with drug delivery and metabolic lability cited as important contributing factors. We have used a mouse model of PDAC: KRASG12D; p53 R172H; pdx-Cre (KPC) that recapitulates the human disease to study dFdC intra-tumoural metabolism.

Methods: LC-MS/MS and NMR were used to measure drug and physiological analytes. Cytotoxicity was assessed by the Sulphorhodamine B assay.

Results: In KPC tumour tissue, we identified a new, Kennedy pathway-linked dFdC metabolite (gemcitabine diphosphate choline (GdPC)) present at equimolar amounts to its precursor, the accepted active metabolite gemcitabine triphosphate (dFdCTP). Utilising additional subcutaneous PDAC tumour models, we demonstrated an inverse correlation between GdPC/dFdCTP ratios and cytidine triphosphate (CTP). In tumour homogenates in vitro, CTP inhibited GdPC formation from dFdCTP, indicating competition between CTP and dFdCTP for CTP:phosphocholine cytidylyltransferase (CCT). As the structure of GdPC precludes entry into cells, potential cytotoxicity was assessed by stimulating CCT activity using linoleate in KPC cells in vitro, leading to increased GdPC concentration and synergistic growth inhibition after dFdC addition.

Conclusions: GdPC is an important element of the intra-tumoural dFdC metabolic pathway in vivo.

Gemcitabine (dFdC) has been the drug used most frequently for patients with pancreatic ductal adenocarcinoma (PDAC) for several decades, but its modest effects are well documented, with median survival of only 6.7 months (Von Hoff et al, 2013). Research has focused on drug delivery and metabolic lability as the potential causes for the poor response rates. Metabolic activation of dFdC in cells is initiated by deoxycytidine kinase (dCK) to give the monophosphate. Further sequential phosphorylation yields the diphosphate and triphosphate, both responsible for the cytotoxic effects of the drug. Gemcitabine diphosphate (dFdCDP) inhibits ribonucleotide reductase, which catalyses formation of deoxynucleotide triphosphates required for DNA synthesis. When incorporated into DNA, gemcitabine triphosphate (dFdCTP) terminates DNA chain elongation (Huang et al, 1991; Plunkett et al, 1995). 2',2'-difluorodeoxyuridine (dFdU) has been considered to be the major inactive metabolite of dFdC; however, its triphosphorylated form dFUtTP may contribute to cytotoxicity (Veltkamp et al, 2008). Metabolism-based approaches to improve dFdC efficacy are ultimately aimed at increasing the amount of dFdCTP and have thus far manipulated nodes in the drug's...
metabolic pathway likely to favour dFdCPT formation, such as reducing cytidine deaminase-mediated dFdU formation (Beumer et al., 2008; Costanzi et al., 2011; Tibaldi et al., 2011). However, such approaches will be informed by knowledge of intra-tumoural metabolism of the drug that has been limited by the scarcity of tissue specimens from patients.

To gain insight into dFdC pharmacology, we recently developed an assay to measure dFdC and its metabolites in tumour tissue from the KrasG12D, p53R172H, pdx-Cre (KPC) genetically engineered mouse model of PDAC (Bapiro et al., 2011). Using the same assay, the likelihood of further metabolism of dFdCPT was also investigated, with a focus on its possible metabolism by enzymes in the Kennedy pathway of phosphatidylcholine (PtdCho) synthesis. The precedent for this is cytosine arabinoside (Ara-C) (Lauzon et al., 1978a,b), the diphosphate choline metabolite of which is thought to be formed from PtdCho and Ara-C monophosphate, in a reversal of the reaction catalysed by cholinephosphotransferase (CPT) (Figure 1; Kucera and Capizzi, 1992). PtdCho is a phospholipid with critical roles in lipid membrane synthesis and signal transduction. The majority of PtdCho is synthesised from choline via the Kennedy pathway in three steps (Figure 1) catalysed by the enzymes choline kinase (CK), CTP:phosphocholine cytidylyltransferase (CCT) and CPT. We hypothesised that dFdCPT could compete with the physiological Kennedy pathway substrate cytidine triphosphate (CTP) for the enzyme CCT, resulting in the formation of gemcitabine diphosphate choline (GdPC) in place of the normal physiological metabolite CDP choline.

Here, we report the identification of GdPC as a major dFdC metabolite in murine PDAC tumour tissue from the KPC genetically engineered mouse. In Mia PaCa-2 xenograft tissue the GdPC/dFdCPT ratio was lower than in KPC PDAC tissue, and in K8484 (KPC PDAC cell line) allograft tissue the GdPC/dFdCPT ratio was higher than in KPC PDAC. Therefore, using these different models of pancreatic cancer, we were able to probe the Kennedy pathway for correlants of the observed GdPC/dFdCPT ratios that could be important determinants of dFdC pharmacokinetics and pharmacodynamics.

**Materials and methods**

**Mouse studies.** All mouse experiments were carried out in accordance with the UK Animals (Scientific Procedures) Act 1986, revised by the Amendment Regulations 2012 (SI 2012/3039) to transpose European Directive 2010/63/EU, with approval from the local Animal Welfare and Ethical Review Body, and following the 2010 guidelines from the United Kingdom Coordinating Committee on Cancer Research (Workman et al., 2010).

KPC mouse model of PDAC has been described previously (Hingorani et al., 2005; Olive et al., 2009). KPC mice develop advanced PDAC from 2 to 3 months and have a shortened median survival of approximately 5 months.

Enrolment of KPC mice in the study was based on tumour size, measured by ultrasound in an axial orientation using the Vevo 770 System (Visual Sonics, Inc., Toronto, ON, Canada) (Cook et al., 2008; Olive et al., 2009). Mice with mean PDAC tumour diameters of 6–9 mm were enrolled.

K8484 is a cell line that was established from a KPC PDAC tumour as described previously (Olive et al., 2009). Control littersmates of KPC mice, p53R172H, Pdx1-Cre (PC) female mice were used in this study to transplant 1 × 10⁶ K8484 cells in PBS subcutaneously into each flank. The mice were dosed with dFdC when the tumours reached at least 200 mm³. Three mice were used per time point (two tumours per mouse).

Subcutaneous xenografts of Mia PaCa-2 cells were established by implanting 5 × 10⁶ cells in the flank of female 9-week-old BALB/c nude mice (Charles River UK Ltd., Margate, UK). The mice were dosed with dFdC when the tumours reached at least 300 mm³. At least three mice were used per time point.

dFdC HCl (Tocris Bioscience, Bristol, UK) was dissolved in sterile 0.9% saline to 20 mg ml⁻¹ and then used to dose the mice. For PK studies, the mice were killed at fixed time points after a single dose of 100 mg kg⁻¹ IP dFdC, and plasma and tumour were then snap-frozen. For efficacy studies, mice were dosed twice per week with 100 mg kg⁻¹ IP dFdC, as used in previous therapeutic studies (Frese et al., 2012; Courtn et al., 2013).

**Identification of GdPC.** To identify GdPC, an LC-MS/MS method for the physiological metabolite CDP choline (C0256, Sigma Aldrich Co Ltd., Dorset, UK) based on the method by (Desoubzdanne et al., 2010) was developed. A Sciex 4000 Q trap mass spectrometer (AB Sciex UK Ltd., Warrington, UK) fitted with a Turbo ionspray source at 500 °C operated in positive mode was used. Quantitative data acquisition was done using the software Analyst ver 1.4.2 (Ab Sciex UK Ltd.). Given the similarities in structure between CDP choline and GdPC (Figure 2A and B), their chromatographic properties were also expected to be similar. PDAC tissue, obtained from a mouse 2 h after IP injection of dFdC (100 mg kg⁻¹), was precipitated using 100% acetonitrile. After centrifugation, the supernatant was transferred to a clean tube and evaporated to dryness. The residue was reconstituted in 75% acetonitrile and injected into the mass spectrometer. An enhanced product ion scan for the expected precursor ion for GdPC (m/z 509) was run (under the same conditions as for the multiple reaction monitoring experiment for CDP choline). The spectra obtained were compared with those of CDP choline to aid identification of GdPC.

**Quantitation of dFdC, dFu, dFdCPT, GdPC, Cytidine, CTP and CDP choline by LC-MS/MS in tumour tissue and cell extracts.** GdPC (Cat. no. G305015) was synthesised by Toronto
Research Chemicals (Toronto, ON, Canada) while CTP and cytidine were purchased from Sigma Aldrich Co Ltd. The analytes in tumour tissues were quantified essentially as previously described (Bapiro et al., 2011). Minor modifications included addition of MRM transitions for GdPC (509–184.05), CTP (484–111.91), cytidine (244–112.04) and CDP choline (489.1–184.05). In addition, the mobile phase gradient starting conditions were modified to 98% ammonium acetate pH 10 and 2% acetonitrile instead of 95% and 5%, respectively. To obtain cell extracts from culture in vitro, cells were harvested by trypsinisation and counted. The cells were then washed with ice-cold PBS, and pellets were obtained by centrifugation at 20 000 g for 20 min. Ice-cold 60% methanol (volume adjusted for number of cells) containing tetrahydrouridine (25 μg ml⁻¹) was added to cell pellets and vortexed vigorously. The cell methanol mixture was incubated at 80 °C for at least 30 min and then sonicated for 10 min in an ice-bath. In all, 50 μl of the cell extract was then processed as described above for the tumour tissue. Absolute concentrations were obtained for dFdC, dFdU, dFdCTP and GdPC, because these are non-endogenous metabolites, and standard curves could be created using non-dFdC-treated tissue or cell homogenates as the blank matrix. CDP choline, CTP and cytidine were expressed as relative concentrations (based on MS peak area ratio of analyte vs internal standard), because these are endogenous metabolites, and so no blank matrix was obtainable to use for standard curves.

Quantitation of phosphocholine, glycerophosphocholine and total choline containing metabolites by NMR. In all, 25 mg of tumour tissue from untreated mice and from mice 4 h post-dFdC (100 mg kg⁻¹) IP were homogenised in 50% acetonitrile using a Precellys homogeniser (Stretton Scientific, Stretton, UK) in reinforced tubes with small ball bearings (Precellys MK28-R) for 250 s at 5800 r.p.m. After centrifugation at 20 000 g for 20 min, the supernatant was transferred to a clean tube and evaporated to dryness. The residue was dissolved in 0.5 ml of D₂O and transferred to a 5 mm standard NMR tube; 10 μl of 10 mM DSS (4,4-dimethyl-4-silapentane-1-sulphonic acid) was then added as an external standard. The NMR tubes were then loaded onto a 600 MHz Bruker Avance NMR spectrometer (Bruker UK Ltd., Coventry, UK). NMR data was then acquired with a water presaturation pulse sequence. ¹H NMR spectroscopic acquisition parameters included 32k time domain data points, 512 averages, repetition delay of 5 s and acquisition time of 2.2 s, resulting in a total acquisition time of 1 h 2 min for each spectrum. The acquired data were Fourier transformed, phase corrected and the baseline was corrected. We used the Bruker TOPSPIN 2.1 software for

---

Figure 2. The identification of GdPC by LC-MS/MS. Chemical structures of (A) the physiological metabolite CDP choline, (B) GdPC and (C) enhanced product ion scan spectrum of GdPC (precursor, at m/z 509) and proposed fragmentation.

---
NMR spectral acquisition and processing and the NMR Suite 7.5 (Chenomx Inc., Edmonton, AB, Canada) software package for identification and quantitation of metabolites. The DSS signal was used to identify the chemical shifts of metabolites and to estimate the absolute metabolite concentrations.

Cell culture. The K8484 cell line was maintained in DMEM (D6429, Sigma Aldrich Co Ltd.) containing 5% FBS (10270-098, Life Technologies Ltd., Paisley, UK). MIA PaCa-2 cells were obtained from the European Collection of Cell Cultures (Public Health England, Salisbury, UK, authenticated by STR genotyping) and maintained in DMEM containing 10% FBS. Gemcitabine (3259, Tocris Bioscience) was dissolved in DMSO; linoleate (L8134, Sigma Aldrich Co Ltd.) and 6-diaz-o-5-oxo-L-norleucine (DON, D2141 Sigma Aldrich Co Ltd.) were dissolved in sterile water. Experiments assessing the effect of DON on dFdC metabolism were carried out in media lacking glutamine (D5671, Sigma Aldrich Co Ltd.). Growth-inhibition assays were carried out using the sulphorhodamine assay, and subsequent synergy calculations were done as previously described (Lin et al., 2012).

Effect of CTP on GdPC formation in tumour homogenate. KPC PDAC tissue homogenised in 0.1 M Tris-Cl buffer pH 7.4 (1:4) was used as the source of CCT enzyme. The reaction mixture in a final volume of 200 μl consisted of tissue homogenate (10 μl), magnesium chloride (8 μl), EDTA (1.8 μl), phosphocholine (1 μl) and Tris-Cl buffer pH 7.4 (0.1 μl). The reaction was started by adding dFdCTP (200 μm) and incubated at 37°C for 30 min, and the reaction was stopped by adding 200 μl of ice-cold acetonitrile (100%). The effect of CTP (200 μm) on GdPC formation was assessed by adding CTP to the reaction mixture. A control sample was incubated under the same conditions, with dFdCTP added after stopping the reaction. After centrifugation at 20 000 g for 20 min, the supernatant was transferred to a clean tube and evaporated to dryness. The residue was reconstituted in 100 μl water, and 15 μl was used for quantitation of GdPC using the LC-MS/MS method mentioned above.

**RESULTS**

Identification and quantitation of GdPC. LC-MS/MS analysis was performed on homogenate from a KPC tumour taken 2 h after a single dose of dFdC. An enhanced product ion spectrum for GdPC of the expected precursor ion m/z 509 yielded spectra adequate for a definitive identification, which was aided by comparison with that of CDP choline m/z 489.2, given their similar structures (Figure 2A–C). The fragment ions at m/z 184.1, 166 and 125 are characteristic of the phosphocholine moiety (Vaezian et al., 2010; Lattanzio et al., 2009; Hayashi et al., 1989; Antonopoulou et al., 2002). A sample of GdPC was then custom-synthesised for use in standard curves for subsequent quantification of GdPC in tumour homogenates.

PDAC models. In order to investigate the significance of GdPC, we next assessed concentrations of dFdCTP and GdPC in in vivo models of pancreatic cancer. dFdC shows little efficacy in KPC mouse PDAC tumours (Olive et al., 2009). The intra-tumoural concentrations of dFdC, dFdU, dFdCTP and GdPC were measured in KPC mice after administration of 100 mg kg$^{-1}$ dFdC, and samples were collected at 1, 2, 4, 6 and 10 h with at least five animals per time point. GdPC and dFdCTP exhibited similar concentration time profiles in KPC mice, and maximum concentrations were observed at about 2 h (Figure 3A). Peak dFdCTP was 6.1 ± 3.9 pmoles mg$^{-1}$ tissue and remained detectable at 10 h in only one of the samples. Peak GdPC was 7.2 ± 3.8 pmoles mg$^{-1}$ at 2 h and below the level of quantification by 10 h. The concentration time profile for dFdC and dFdU in the same samples is shown in Supplementary Figure S1A. We then investigated whether GdPC could be detected in other in vivo...
pancreatic cancer models used in our laboratory – first, in subcutaneous allografts of a cell line K8484 derived from a KPC PDAC tumour. This allograft model responds very well to dFdC (Figure 3D). For PK analysis, K8484 cells were transplanted subcutaneously into syngeneic Kras<sup>Wt</sup>; p53<sup>R172H</sup>, Pdx1-Gcre (PC) mice, and once the tumours had grown sufficiently, a single dose of dFdC (100 mg kg<sup>-1</sup>, IP) was administered. Tumour tissue samples were collected at 0.25, 0.5, 1, 2, 4 and 24 h and were used to quantify dFdC and metabolites. To our surprise and in contrast to results in the KPC mouse tumour tissue, GdPC was the predominant metabolite, with at least a four-fold higher AUC than dFdCTP (Figure 3B). The peaks were maximal at 1 and 2 h for dFdCTP and GdPC, respectively, and both metabolites were below the limit of quantification at 24 h. Of note, the absolute dFdCTP concentrations in the K8484 allograft (peak 3.0 ± 2.0 pmoles mg<sup>-1</sup>) were lower than those in the KPC model, but the GdPC concentrations were much higher (peak 16.4 ± 4.1 pmoles mg<sup>-1</sup>). The concentration time profile for dFdC and dFdU in the same tumours is shown in Supplementary Figure S1B.

While mindful of the complexities of comparing different species, we have also assessed amounts of dFdCTP and GdPC in the MIA PaCa-2 xenograft, another model that is sensitive to growth inhibition by dFdC (Figure 3E). In MIA PaCa-2 xenograft PK studies, after a single dose of dFdC, dFdCTP was the predominant metabolite over GdPC (Figure 3C), the opposite result to that seen in K8484 allografts. The peak concentration of dFdCTP, at 4 h, was 10.2 ± 5.0 pmoles mg<sup>-1</sup> and that of GdPC was 1.6 ± 0.5 pmoles mg<sup>-1</sup>. Again, both metabolites were below the limit of quantification at 24 h. The concentration time profile for dFdC and dFdU in the same tumours is shown in Supplementary Figure S1C. Representative H&E images of tumour sections from each of the three models are shown in Supplementary Figure S2.

We next investigated whether differences in Kennedy pathway intermediates could explain the differences in amounts of dFdCTP and GdPC observed in the different <i>in vivo</i> models of pancreatic cancer.

**Comparison of Kennedy pathway intermediates in tumour tissue from <i>in vivo</i> PDAC models.**<sup>1</sup> <i>H</i> HR NMR spectroscopy was used to measure concentrations of Kennedy pathway intermediates phosphocholine, glycerophosphocholine and total choline-containing metabolites in tumour homogenates from KPC PDAC, K8484 allografts and MIA PaCa-2 xenografts taken before and 4 h after IP administration of dFdC (100 mg kg<sup>-1</sup>) (Supplementary Figure S3). No differences were observed in the concentrations of the Kennedy pathway metabolites between samples from dFdC-dosed and untreated mice in each group. The only significant difference was in the phosphocholine/glycerophosphocholine ratio, when dFdC-dosed K8484 allografts were compared with dFdC-dosed MIA Paca-2 xenografts (Supplementary Figure S3C). Using our LC-MS/MS assay, we then quantified relative levels of CDP choline and CTP in tumour homogenates of mice from the three different models taken 2 h after administration of dFdC. Although no significant difference was observed in the relative concentrations of CDP choline (Figure 4A), both CTP and cytidine exhibited an inverse correlation with the concentration of GdPC (Figure 4B and D). The K8484 allografts had the highest concentrations of GdPC and the lowest concentrations of CTP, while MIA PaCa-2 xenografts had the lowest GdPC but highest CTP concentration. We hypothesised that the inverse correlation between CTP and GdPC might be caused by inhibition of GdPC formation by CTP. Therefore an <i>in vitro</i> assay was established to measure formation of GdPC using a
homogenate of KPC PDAC tissue as an enzyme source and dFdCTP as the substrate, and this assay was used to assess the effect of CTP. CTP was found to be an inhibitor of GdPC formation (Figure 4E). Treating K8484 cells in vitro with the CTP synthase inhibitor DON resulted in >50-fold reduction in CTP levels, accompanied by a 15-fold increase in the GdPC concentration (Supplementary Figure S4), confirming that CTP inhibits GdPC formation.

Investigation of whether GdPC contributes to dFdC anti-tumour activity. Comparison of the GdPC/dFdCTP profiles in the three in vivo models (Figure 3) with the relative efficacy of dFdC in those models suggests a role for GdPC in dFdC anti-tumour activity assessed on the basis of effect on tumour volume. After adding dFdC (100 nM) to K8484 cells in vitro, in sharp contrast to the results with K8484 allografts in vivo, it was apparent that dFdCTP (Figure 5A) was the predominant metabolite rather than GdPC (Figure 5B), and in other PDAC cell lines incubated with dFdC the in vitro GdPC concentration was rarely above the lower limit of quantification (data not shown). Attempts to assess the cytotoxicity of GdPC by adding increasing concentrations of the compound to cells in culture failed, because it was degraded to dFdC in the culture medium (even in the absence of cells) – the highest concentration used, 300 nM of GdPC, was almost completely converted to dFdC within 24 h of incubation at 37 °C (data not shown). Thus, manipulation of the intracellular generation of GdPC was felt to be the only feasible approach to assess its impact on cytotoxicity. Linoleic acid has been shown to activate CCT and synthesis of PtdCho (Mallampalli et al., 1998; Burkhardt et al., 1988), so we assessed the effects of adding linoleic acid on the cytotoxic effects of dFdC in K8484 cells using an 8 × 8 concentration combination assay, incubating for 72 h. We observed significant synergistic effects with E\textsubscript{max} of 99% growth inhibition at 10 nM dFdC and 170 μM linoleate, compared with a prediction of 57% growth inhibition if the effect of the two drugs were additive in accordance with the Bliss Additivity model (Figure 5C). Shorter incubations with 170 μM linoleate were used to assess its effect on dFdC (100 nM) metabolism: dFdCTP concentrations were unaffected by linoleate (Figure 5A), but there was a 10-fold increase in GdPC concentration at 2.5 h, and it continued to be higher over 10 h (Figure 5B). Thus linoleate increased the cellular GdPC concentration after dFdC administration and enhanced dFdC cytotoxicity synergistically.

DISCUSSION

For the past two decades, dFdC alone or in combination has been the standard of care for PDAC (reviewed in Michl and Gress, 2013), with few new therapeutic advances resulting in improved survival. One exception is FOLFIRINOX, a combination devoid of dFdC which recently showed increased survival in PDAC (Conroy et al., 2011) but is too toxic to be used routinely in the majority of patients. dFdC combinations continue to be important, as exemplified by results of the recently completed phase III trial of a nab-paclitaxel/dFdC combination (Von Hoff et al., 2013). Part of the mechanism of efficacy of this combination may be the ability of nab-paclitaxel to enhance dFdC efficacy via modulation of its metabolism by cytidine deaminase (Frese et al., 2012). We have now used the KPC model to shed new light on the intra-tumoural metabolism of dFdC with the hope of uncovering novel metabolic targets with potential to improve the drug’s efficacy. We have

Figure 5. The effect of the combination of linoleate and gemcitabine in K8484 cells. The timecourse of production of (A) dFdCTP and (B) GdPC in K8484 cells grown in DMEM supplemented with 5% FBS and treated over 10 h with linoleate (170 μM) and dFdC (100 nM). Results are the mean ± s.d. of three replicates. (C) Effect on growth of K8484 cells using the sulphorhodamine B cytotoxicity assay, exposed to an 8 × 8 combination of linoleate and dFdC for 72 h. The left panel shows the experimental data (mean of three independent experiments, each done in triplicate) and shows the percentage of growth inhibition compared with DMSO control. A Bliss additivity model built from the experimental single agent data shows the predicted growth inhibition if the combination were additive (middle). The right panel shows the difference values after subtracting the predicted values from the experimental data, with difference values of >25 considered to show synergy (in blue).
shown here that the Kennedy pathway-linked GdPC is a major metabolite of dFdC in vivo. The metabolic pathway by which it is formed is shown in Figure 6.

Compounds analogous to this CDP choline metabolite have been shown to be formed from compounds with similar structures to dFdC, including 2',3'-dideoxyctydine (zalcitabine), zebularine and arabinofuranosycytosine (ara-C) (Lauzon et al, 1978a,b; Rossi et al, 1999; Ben-Kasus et al, 2005). An unidentified metabolite X, making up 2.8% of total dFdC, was reported in Chinese Hamster Ovary cells in studies using radiolabeled dFdC (Heinemann et al, 1988), which they suggested could be the ‘CDP choline analogue similar to that found in cells treated with ara-C’. As shown by our in vitro studies, in cultured cells, dFdCTP is the predominant metabolite rather than GdPC, with GdPC concentrations rarely above the limit of quantification, which explains why dFdC metabolism experiments conducted in cultured cells would probably fail to detect GdPC as an important metabolite.

The three in vivo PDAC models showed different intra-tumoural GdPC:dFdCTP ratios that inversely correlated with CTP concentrations, a feature that was explained by the inhibition of GdPC formation by CTP observed in vitro using tumour homogenates. It is, however, not clear why there are differences in the CTP concentrations. An important difference of the models used relates to their stromal component. The fact that we are able to detect GdPC in both subcutaneous xenografts (which have little stroma) and the authochthonous PDAC in KPC mice (with extensive stroma) suggests that its production is not specific to tumour stroma. Generating the metabolite X, making up 2.8% of total dFdC, was reported in Chinese Hamster Ovary cells in studies using radiolabeled dFdC (Heinemann et al, 1988), which they suggested could be the ‘CDP choline analogue similar to that found in cells treated with ara-C’. As shown by our in vitro studies, in cultured cells, dFdCTP is the predominant metabolite rather than GdPC, with GdPC concentrations rarely above the limit of quantification, which explains why dFdC metabolism experiments conducted in cultured cells would probably fail to detect GdPC as an important metabolite.

Figure 6. The proposed point at which dFdC metabolism interacts with the Kennedy pathway that converts choline to phosphatidylcholine, resulting in formation of GdPC, and the impact of linoleate on that reaction.

increased GdPC concentration is not clear. The equivalent metabolite of ara-C at very high concentrations (400 μM) is thought to cause excessive formation of PtdCho resulting in cell lysis (Daly et al, 1990) but is unlikely to be the case in our study because a 1000-fold lower concentration of dFdC was used. The clinical relevance of our findings is supported by reports of an ongoing clinical trial suggesting better outcomes in pancreatic cancer patients treated with dFdC and the fish oil formulation Lipidem (B. Braun Melsungen AG, Melsungen, Germany), one of whose major constituents is linoleic acid (Arshad et al, 2013a,b). We believe that Lipidem may promote formation of the active form of CCT and might also increase tumoural concentrations of GdPC.

In conclusion, we have established GdPC as an important element of the dFdC metabolic pathway in tumour tissue in mouse models of PDAC and shown that its formation may contribute to dFdC cytotoxicity.

ACKNOWLEDGEMENTS

We thank the CRUK Cambridge Institute BRU staff for assistance with mouse studies and Donna-Michelle Smith and Michael Williams for advice on LC-MS/MS. TEB, AC, JLB and FMR were funded by Cancer Research UK programme grant C96/A8333 Senior Group Leader Funding to DJI, KKF, NC and AN were funded by Cancer Research UK Senior Group Leader Funding to DAT. BM was funded by Cancer Research UK Senior Group Leader Funding to JRG.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

Antonopoulou S, Oikonomou A, Karantonis HC, Fragopoulou E, Pantazidou A (2002) Isolation and structural elucidation of biologically active phospholipids from Scytonema julianum (cyanobacteria). Biochem J 367(Pt 1): 287–293.

Arshad A, Chung W, Isherwood J, Steward W, Metcalfe M, Dennison A (2013a) Restoration of mammone-binding lectin complement activity is associated with improved outcome in patients with advanced pancreatic cancer treated with gemcitabine and intravenous omega-3 fish oil. JPEJ/Parenter Enteral Nutr 38(2): 214–219.

Arshad A, Chung NY, Steward W, Metcalfe MS, Dennison AR (2013b) Reduction in circulating pro-angiogenic and pro-inflammatory factors is related to improved outcomes in patients with advanced pancreatic cancer treated with gemcitabine and intravenous omega-3 fish oil. HPB (Oxford) 15(6): 428–432.

Bapio TE, Richards FM, Goldgraben MA, Olive KP, Madhu B, Frese KK, Cook N, Jacobetz MA, Smith DM, Tuveson DA, Griffiths JR, Jodrell DI (2011) A novel method for quantification of gemcitabine and its metabolites 2’-2’-difluoro-2’-deoxycytidine and gemcitabine triphosphate in tumour tissue by LC-MS/MS: comparison with 19F NMR spectroscopy. Cancer Chemother Pharmacol 68(5): 1243–1253.

Ben-Kasus T, Ben-Zvi Z, Marquez VE, Kelley JA, Agbaria R (2005) Metabolic activation of zebularine, a novel DNA methylation inhibitor, in human bladder carcinoma cells. Biochem Pharmacol 70(1): 121–133.

Beumer JH, Eiseman JL, Parise RA, Joseph E, Covey JM, Egorin MJ (2008) Modulation of gemcitabine (2’-2’-difluoro-2’- deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrodouridine. Clin Cancer Res 14(11): 3529–3535.

Burkhardt R, Von Wichert P, Batenburg JJ, Van Golde LM (1988) Fatty acids stimulate phosphatidylcholine synthesis and CTP:choline-phosphate cytidylyltransferase in type II pneumocytes isolated from adult rat lung. Biochem J 254(2): 495–500.
Conroy T, Desegnine F, Ychou M, Bouche O, Guimbaud R, Becoarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Benouenna J, Bachet JB, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. *N Engl J Med* 364(19): 1817–1825.

Cook N, Olive KP, Frese K, Tuveson DA (2008) K-Ras-driven pancreatic cancer mouse model for anticancer inhibitor analyses. *Methods Enzymol* 439: 73–85.

Costanzo S, Vilar S, Micozzi D, Carpi FM, Ferino G, Vita A, Vincenzetti S (2011) Delineation of the molecular mechanisms of nucleoside recognition by cytidine deaminase through virtual screening. *Chem Med Chem* 6(8): 1452–1458.

Courtin A, Richards FM, Bapiro TE, Bramhall JL, Neesse A, Cook N, Krippendorff BF, Tuveson DA, Jodrell DI (2013) Anti-tumour efficacy of capcetitabine in a genetically engineered mouse model of pancreatic cancer. *PLoS One* 8(6): e67330.

Daly PF, Zugmaier G, Sandler D, Carpen M, Myers CE, Cohen JS (1990) Regulation of the cytidine phospholipid pathways in human cancer cells and effects of 1-beta-D-arabinofuranosylcytosine: a noninvasive 31P nuclear magnetic resonance study. *Cancer Res* 50(3): 552–557.

Desoubzdanne D, Claparols C, Martins-Froment N, Zedde C, Balayssac S, Gilar V, Terce F, Martino R, Malet-Martino M (2010) Analysis of hydrophilic and lipophilic choline compounds in radiosensitive and radiosensitive gliblastoma cell lines by HILIC-ESI-MS/MS. *Ann Bioanal Chem* 398(6): 2723–2730.

Fagone P, Jackowski S (2013) Phosphatidylcholine and the CDP-choline cycle. *Biochim Biophys Acta* 1831(3): 523–532.

Frese KK, Neesse A, Cook N, Bapiro TE, Lokkema MP, Jodrell DI, Tuveson DA (2012) nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. *Cancer Discov* 2(3): 260–269.

Hayashi A, Matsubara T, Morita M, Kinoshita T, Nakamura T (1989) Structural analysis of choline phospholipids by fast atom bombardment mass spectrometry and tandem mass spectrometry. *J Biochem* 106(2): 264–269.

Heinemann V, Hertel LW, Grindey GB, Plunkett W (1988) Analysis of hydrophilic and lipophilic choline compounds in radioresistant and radiosensitive glioblastoma cell lines by HILIC-ESI-MS/MS. *Ann Bioanal Chem* 398(6): 2723–2730.

Fagone P, Jackowski S (2013) Phosphatidylcholine and the CDP-choline cycle. *Biochim Biophys Acta* 1831(3): 523–532.

Frese KK, Neesse A, Cook N, Bapiro TE, Lokkema MP, Jodrell DI, Tuveson DA (2012) nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. *Cancer Discov* 2(3): 260–269.

Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W (1991) Action of gemcitabine diphosphate choline in PDAC models. *Ann Oncol* 24(1 Suppl 1): 3–10.

Lauzon GJ, Paterson AR, Belch AW (1978b) Formation of 1-beta-D-arabinofuranosylcytosine diphosphate choline in neoplastic and normal cells. *Cancer Res* 38(6): 1723–1729.

Michl P, Gress TM (2013) Current concepts and novel targets in advanced pancreatic cancer. *Nat Rev Dis Primers* 2(2): 317–326.

Neeese A, Frese KK, Bapiro TE, Nakagawa T, Sternlicht MD, Seeley TW, Pilsarky C, Jodrell DI, Spong SM, Tuveson DA (2013) CTGf antigen with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. *Proc Natl Acad Sci USA* 110(30): 12325–12330.

Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK, Denicola G, Feig C, Combs C, Winter SP, Ireland-Zecchini H, Reichelt S, Howat WJ, Chang A, Dhara M, Wang L, Ruckett F, Grutzmann R, Pilarsky C, Izarderjene K, Hingorani SR, Huang P, Davies SE, Plunkett W, Egorin M, Hruban RH, Whitebread N, McGovern K, Adams J, Jacobozio-Danahue C, Griffiths J, Tuveson DA (2009) Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. *Science* 324(5933): 1457–1461.

Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V (1995) Gemcitabine: metabolism, mechanisms of action, and self-potentiation. *Semin Oncol* 22(4 Suppl 1): 11–30.

Rizzi L, Serafini S, Schiavano GF, Casabianca A, Vallanti G, Ghiaartanti L, Magnani M (1999) Metabolism, mitochondrial uptake and toxicity of 2',3'-dideoxycytidine. *Biochem J* 344(Pt 3): 915–920.

Bilaldi C, Giovannietti E, Tiseo M, Leon LG, D'Incecco A, Loocoek N, Bartolotti M, Honeywell R, Cappuzzo F, Ardizzone A, Peters GJ (2011) Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-platinum-treated advanced non-small-cell lung cancer patients. *Ann Oncol* 23(3): 670–677.

Vaezian B, Anderton CR, Kraft ML (2010) Discriminating and imaging different phosphatidylcholine species within phase-separated model membranes by principal component analysis of TOF-secondary ion mass spectrometry images. *Anul Chem* 82(4): 10006–10014.

Velkamp SA, Pluim D, van Eijndhoven MA, Bolijn MJ, Ong FH, Govindarajan R, Unadkat JD, Beijnen JH, Schellens JH (2008) New insights into the pharmacology and cytotoxicity of gemcitabine and 2',2'-difluorodeoxycytidine. *Mol Cancer Ther* 7(8): 2415–2425.

Von Hoff DD, Ervin T, Arena FP, Chiorian EG, Infante J, Moore M, Seay T, Tuljandia SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramathan RK, Taberner J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF (2013) Increased survival in pancreatic cancer with nab-Paclitaxel plus gemcitabine. *N Engl J Med* 369(18): 1691–1703.

Workman P, Aboagye EO, Ballowill F, Balmain A, Bruder G, Champion DJ, Double JA, Everitt J, Farningham DA, Gellie MJ, Kelland LR, Robinson DJ, Stratford II, Tozer GM, Watson S, Wedge SR, Eccles SA. Committee of the National Cancer Research I (2010) Guidelines for the welfare and use of animals in cancer research. *Br J Cancer* 102(11): 1555–1577.

This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/

Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)